After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with ...

Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

The injunction had temporarily barred Sun Pharma from launching Leqselvi in the United States due to an ongoing legal battle with Incyte Corporation. The appellate court's decision, which came shortly ...

Photograph: Francis Mascarenhas/Reuters Recent acquisitions, a favourable court ruling in the case of the hair loss drug ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Sun Pharma had appealed against the District of New Jersey’s decision that had previously granted a preliminary injunction delaying its launch of Leqselvi (deuruxolitinib) in the United States.

Photograph: Francis Mascarenhas/Reuters The US Court of Appeals for the Federal Circuit has paved the way for the launch of Leqselvi in the US, after almost a year of legal battle over the patent.

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...

Sun Pharma has been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib). On April 9, 2025, the US Court of Appeals for the Federal Circuit held an ...

Indian benchmark Nifty 50 spent the day in the green. Nifty opened at 24,070 and ended the day at 24,329 gaining 289 points. It regained Friday’s losses and saw high momentum today. Out of the total ...